Description: Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Home Page: hemostemix.com
707-7th Avenue SW
Calgary,
AB
T2P 3H6
Canada
Phone:
905-580-4170
Officers
| Name | Title |
|---|---|
| Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, CEO & Director |
| Ms. Christina Wu CPA | Interim Chief Financial Officer |
| Mr. Peter Pavlin | Vice President of Operations |
| Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 39.2259 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |